BioCardia (BCDA) Competitors $2.08 +0.08 (+4.00%) Closing price 03:59 PM EasternExtended Trading$2.09 +0.01 (+0.48%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. PRLD, CELU, LIAN, ALGS, ABVC, ATNM, MURA, SCLX, GRCE, and STTKShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Prelude Therapeutics (PRLD), Celularity (CELU), LianBio (LIAN), Aligos Therapeutics (ALGS), ABVC BioPharma (ABVC), Actinium Pharmaceuticals (ATNM), Mural Oncology (MURA), Scilex (SCLX), Grace Therapeutics (GRCE), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Prelude Therapeutics Celularity LianBio Aligos Therapeutics ABVC BioPharma Actinium Pharmaceuticals Mural Oncology Scilex Grace Therapeutics Shattuck Labs Prelude Therapeutics (NASDAQ:PRLD) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Does the media favor PRLD or BCDA? In the previous week, BioCardia had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for Prelude Therapeutics. BioCardia's average media sentiment score of 1.36 beat Prelude Therapeutics' score of 0.63 indicating that BioCardia is being referred to more favorably in the news media. Company Overall Sentiment Prelude Therapeutics Positive BioCardia Positive Do analysts recommend PRLD or BCDA? Prelude Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 462.50%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 1,101.92%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is PRLD or BCDA more profitable? Prelude Therapeutics' return on equity of -89.18% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -89.18% -69.26% BioCardia N/A -30,792.60%-223.06% Do institutionals and insiders hold more shares of PRLD or BCDA? 79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Comparatively, 20.0% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, PRLD or BCDA? Prelude Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Which has preferable earnings & valuation, PRLD or BCDA? BioCardia has lower revenue, but higher earnings than Prelude Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M6.45-$127.17M-$1.69-0.47BioCardia$60K179.57-$7.95M-$2.33-0.89 SummaryPrelude Therapeutics beats BioCardia on 9 of the 16 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.36M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.8921.3126.1719.90Price / Sales179.57278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book11.567.518.055.38Net Income-$7.95M-$55.05M$3.15B$248.50M7 Day Performance-7.56%2.45%1.85%2.97%1 Month Performance-7.96%7.33%4.81%6.02%1 Year Performance-29.25%5.38%34.86%20.39% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.7028 of 5 stars$2.08+4.0%$25.00+1,101.9%-33.1%$10.36M$60K-0.8940Positive NewsInsider TradePRLDPrelude Therapeutics3.2687 of 5 stars$0.81+3.1%$4.50+456.0%-78.8%$44.34M$7M-0.48120CELUCelularity0.1379 of 5 stars$1.96+5.9%N/A-35.7%$44.31M$54.22M-0.74220News CoveragePositive NewsGap UpLIANLianBioN/A$0.41+1.2%N/A+34.9%$44.31MN/A-0.51110ALGSAligos Therapeutics4.2166 of 5 stars$7.21flat$70.00+870.9%-19.9%$44.08M$3.94M-0.4190Positive NewsABVCABVC BioPharma0.3487 of 5 stars$2.22-14.3%N/A+195.2%$43.98M$510K-17.0830High Trading VolumeATNMActinium Pharmaceuticals2.3337 of 5 stars$1.40-1.4%$4.00+185.7%N/A$43.67M$81K-1.0130News CoverageMURAMural Oncology3.5399 of 5 stars$2.47-0.4%$12.00+385.8%-19.6%$42.83MN/A-0.32119Positive NewsSCLXScilex2.152 of 5 stars$5.89-2.6%$455.00+7,625.0%-90.8%$42.06M$56.59M-0.2080News CoverageGRCEGrace Therapeutics2.1862 of 5 stars$2.97flat$12.00+304.0%N/A$41.07MN/A-3.34N/APositive NewsSTTKShattuck Labs3.3554 of 5 stars$0.79-7.3%$7.50+847.2%-79.6%$40.89M$5.72M-0.57100News Coverage Related Companies and Tools Related Companies PRLD Alternatives CELU Alternatives LIAN Alternatives ALGS Alternatives ABVC Alternatives ATNM Alternatives MURA Alternatives SCLX Alternatives GRCE Alternatives STTK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
